Definitive Contract 75N93026C00007
Award Date 7/1/26
Potential Completion Date 6/30/29
Potential Value $4.5M
Federal Agency
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
New York, NY 10013, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
18
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Ceramedix Holding, LLC was awarded a $4.22M cost-plus-fixed-fee definitive contract by the National Institute of Allergy and Infectious Diseases on July 1, 2023, to develop anticeramide treatment as a novel medical countermeasure for the acute effects of radiation exposure. The contract, with performance completing June 30, 2027, supports the NIH's broader mission to develop safe and effective countermeasures that reduce radiation-associated mortality and morbidity in mass casualty incidents....
- The National Institute of Allergy and Infectious Diseases awarded a $4.5 million definitive contract to Micron Biomedical Inc. for development of radiation and nuclear medical countermeasures and biodosimetry devices on July 1, 2026, with no set-aside. The contract encompasses development of a toll-like receptor 5 agonist dissolving microneedle patch for radiation and nuclear medical applications. Place of performance is Atlanta, Georgia. The period of performance runs from July 1, 2026...
- The National Institute of Allergy and Infectious Diseases awarded a $4.477 million definitive contract to Asell, LLC for development of radiation and nuclear medical countermeasures and biodosimetry devices on July 1, 2026. The originating solicitation calls for advanced development and validation of the CellRadx qualitative biodosimetry triage test, with performance running from July 1, 2026 through June 30, 2027 under a base period, and extending to an ultimate completion date of June 30,...
- The National Institute of Allergy and Infectious Diseases awarded a $4.5 million definitive contract to Chromologic LLC for development of radiation and nuclear medical countermeasures (MCMs), biodosimetry devices, and an engineered probiotic therapeutic (LR-IFN-Beta) for gastrointestinal acute radiation syndrome mitigation on July 1, 2026, with no set-aside used. The contract runs through June 30, 2029. Place of performance is Monrovia, California. Chromologic is a minority-owned small...
- This is a $6,150,127.06 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to BCN Biosciences LLC for the development of medical countermeasures to mitigate and/or treat radiation-induced lung injury after a radiological/nuclear incident. The contract has an ultimate completion date of April 30, 2019 and does not have a set-aside designation. Based on the major program code, this contract supports NIAID's efforts to develop...
- This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Meabco Inc. for the "ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2" project. The contract has a ceiling value of $6,434,348.32 and a period of performance ending on April 30, 2025. The contract stems from a Broad Agency Announcement (BAA) seeking proposals to develop safe and effective medical countermeasures to...
- The National Institute of Allergy and Infectious Diseases (NIAID) of the Department of Health and Human Services awarded a $6,620,728 cost-plus-fixed-fee contract to Xequel Bio, Inc. (doing business as FSR) to develop a topical therapeutic called GRANEXIN to mitigate cutaneous radiation injury. This contract was awarded under a prior NIAID Broad Agency Announcement that sought proposals for advanced development of medical countermeasures, including those targeting radiation exposure. The...
- <p>This is a cost-plus-fixed-fee contract awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to RxBio, Inc., a for-profit organization, for the IND-enabling development of RX100 as a medical countermeasure for gastrointestinal acute radiation syndrome. The contract has a potential value of $4,591,511.92 and a completion date of October 31, 2022. The contract was not set aside for any specific business type.</p>
- This is a $36,967,744.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Asell, LLC for the advanced development, validation, and FDA clearance of the CellRadX point-of-care biodosimetry system. The contract is not set-aside. This contract was awarded under a Broad Agency Announcement (BAA) solicitation from the Biomedical Advanced Research and Development Authority (BARDA) seeking proposals for the advanced...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,624,116.99 definitive contract to the University of Wisconsin System to provide centralized dosimetry guidance and monitoring of radiation sources and irradiation protocols across institutions funded by NIAID's Radiation Nuclear Countermeasures Program (RNCP) portfolio. The contract, which has no set-aside designation, was awarded on June 1, 2020 and runs through May 31, 2025. The contractor will be responsible for...